Cancer Focus — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

ISA Pharmaceuticalsisa-pharma.comJan 2023

Netherlands-based developer of fully synthetic immune therapies against cancer and persistent viral infections using a synthetic long peptide platform.

Co-investorsInvest-NL Regeneron Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.